Evidence map›Paper›PMID 38770551›Full record

ArticleCancer medicine2024

Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.

Enver Aydilek, Gerald Wulf, Friedrich Schwarz, Ulrike Bacher, Mathias Rummel, Olga Stiefel, Andrea Kerkhoff, Markus Maulhardt, Thomas Melchardt, Thomas Pabst and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Enver AydilekDepartment for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0003-1418-2725
Gerald WulfDepartment for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Friedrich SchwarzDepartment for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0009-0001-1167-8365
Ulrike BacherDepartment of Hematology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.ORCID 0000-0001-8771-947X
Mathias RummelDepartment of Hematology, Clinic for Haematology and Medical Oncology, Justus Liebig University Hospital, Gießen, Germany.
Olga StiefelDivision of Hematology With Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Linz, Austria.
Andrea KerkhoffDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
Markus MaulhardtDepartment for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Thomas MelchardtDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, Salzburg, Austria.
Thomas PabstDepartment of Medical Oncology, Inselspital Bern University Hospital, Bern, Switzerland.
Georg LenzDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
Evgenii ShumilovDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMantle cell lymphoma (MCL) is a type of B-cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real-world data are scarce.

methodsIn this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).

resultsOn average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow-up of 8.6 months, the mean duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.

conclusionsIn summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.

Indexed as

Compassionate Use TrialsLymphoma, Mantle-CellAdultAgedAged, 80 and overDrug Resistance, NeoplasmEuropeFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalProtein Kinase InhibitorsRetrospective StudiesTreatment OutcomeProtein Kinase Inhibitorscompassionate use programmantle cell lymphomaoutcomespirtobrutinib

Identifiers

PMID38770551
PMCPMC11106640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.